Targeting CCR2/5 in the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.

Targeting CCR2/5 in the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges. Expert Opin Investig Drugs. 2020 Jan 17;: Authors: Lefere S, Devisscher L, Tacke F PMID: 31952447 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research